No abstract

and 5. 87 ± 4.36 (p-value = 0.193)24 hours after admission, 3.06 ± 2.74and 4.93 ± 4.69 (p-value = 0.061)2 weeks later, 2.39 ± 2.41 and 3.66 ± 4.98 (p-value = 0.2 25) one month later, and, 1.07 ± 2.12 and 2.36 ± 2.28 (p-value = 0.511) 3 months later respectively, which were not statistically significant. Also, the relationship between MMP9 and NIHSS was evaluated using Pearson correlation coefficient. There was no significant correlation between MMP9 changes and neurological deficits in any of the time intervals. In both intervention and control groups, the amount of MMP9 24 hours after injection was decreased dramatically (p-value = 0.000) and showed that MMP9 reduction was not dependent on NAC injection. ConclusionsNAC injection did not show clinical and laboratory benefits in patients with AIS in addition to standard therapy.